We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for lenacapavir (Gilead Sciences Pty Ltd)
Active ingredients
lenacapavir
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
[TRADENAME], in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatrics weighing at least 35 kg with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations.
Therapeutic area
Infectious diseases